According to Hovione Technology, the company has acquired global development and commercialization rights to the Papillon multi-use dry powder inhaler from its inventor, Klaus-Dieter Beller. The blister-based DPI is reusable and formed from a single part, “enabling ultra-affordable drug therapies at global scale,” the company said.
The Papillon device will join several other DPIs in Hovione Technology’s offerings, including the Twin Caps DPI and the Large Dose DPI. In 2017, Hovione and H&T Presspart announced a partnership for the capsule-based PowdAir DPI.
Hovione Technology CEO Peter Villax commented, “This is a strategic DPI development for Hovione Technology which emphasizes our long-term commitment to offer market access to a portfolio of innovative inhalers that maximize simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialization of this innovative blister DPI”.